Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03491605
Recruiting Observational

Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection

NCT03491605 · tracked via the Priya Life Science China tracker
Sponsor
Huazhong University of Science and Technology
Phase
Observational
Started
2019-07-01
Last updated
2021-02-10

Condition(s) studied

EBV Infection

Investigational drug(s) / intervention(s)

peripheral EBV-DNA load

peripheral EBV-DNA load: No intervention

Study summary

Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. immunocompetent subjects who was found to have high EBV-DNA load （\>1×103 copies/ml）in peripheral blood during the physical examination 2. Willing to be followed up by telephone or face-to-face interview Exclusion Criteria: 1. Subjects with defined immunodeficiency 2. Subjects who have taken or are going to take immunosuppressive drugs. 3. Subjects Diagnosed a validated hematopathy 4. Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year. 5. psychological illness which does not allow subjects to understand the study and participate following his own free will 6. Pregnant woman 7. no written informed consent

Primary outcome measure(s)

  • hematological malignancies — Five years or more if necessary
    including Burkitt lymphoma, EBV+ B-cell lymphoproliferative diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia (ANKL), classic Hodgkin lymphoma, and Chronic active Epstein-Barr virus infection (CAEBV).

Trial sites (1)

FacilityCityRegionStatus
Tongji hospital, Tongji medical collage of HUST Wuhan Hubei Recruiting

More Huazhong University of Science and Technology trials in China

The ED95 of Ciprofol for Laryngeal Mask Airway Insertion With Fentanyl in Children: A Biased-Coin Dose-Finding Trial Recruiting
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes Recruiting
Analysis of the Incidence and Risk Factors of Chronic Pain After Cesarean Section Recruiting
Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions Starting soon
QLESP Block Versus PENG+LFCN Block for Total Hip Arthroplasty Recruiting

Other trials for the same condition

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Active, not recruiting
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03491605 on ClinicalTrials.gov ↗ ← All trials in China